0001209191-23-016935.txt : 20230307
0001209191-23-016935.hdr.sgml : 20230307
20230307180025
ACCESSION NUMBER: 0001209191-23-016935
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230303
FILED AS OF DATE: 20230307
DATE AS OF CHANGE: 20230307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Daly Jason B.
CENTRAL INDEX KEY: 0001906486
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38485
FILM NUMBER: 23714174
MAIL ADDRESS:
STREET 1: 400 CROSSING BLVD
STREET 2: 3RD FLOOR
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001723128
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
BUSINESS PHONE: (908) 947-3120
MAIL ADDRESS:
STREET 1: 400 CROSSING BOULEVARD
STREET 2: 3RD FLOOR
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: Atlas Holdings, Inc.
DATE OF NAME CHANGE: 20171117
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-03
0
0001723128
Amneal Pharmaceuticals, Inc.
AMRX
0001906486
Daly Jason B.
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BOULEVARD
BRIDGEWATER
NJ
08807
0
1
0
0
SVP, Chief Legal Officer
Class A Common Stock
2023-03-03
4
M
0
22645
A
22645
D
Class A Common Stock
2023-03-03
4
F
0
8164
1.92
D
14481
D
Restricted Stock Units
2023-03-03
4
M
0
22645
0.00
D
Class A Common Stock
22645
67935
D
Restricted Stock Units
2023-03-03
4
A
0
152905
0.00
A
Class A Common Stock
152905
152905
D
Performance-Based Restricted Stock Units
2023-03-03
4
A
0
305810
0.00
A
Class A Common Stock
305810
305810
D
Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
The restricted stock units vest in four equal annual installments beginning on March 3, 2024.
Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Represents a performance-based restricted stock unit grant of 152,905 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period.
Exhibit 24-Power of Attorney
/s/ Denis Butkovic, Attorney-in-Fact
2023-03-07
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents that the undersigned, does hereby make, constitute
and appoint Denis Butkovic and Chris Daly as a true and lawful attorney-in-fact
of the undersigned with full powers of substitution and revocation, for and in
the name, place and stead of the undersigned (in the undersigned's individual
capacity), to execute and deliver such forms that the undersigned may be
required to file with the U.S. Securities and Exchange Commission as a result of
the undersigned's ownership of or transactions in securities of Amneal
Pharmaceuticals, Inc. pursuant to Sections 13(d), 13(g) and 16(a) of the
Securities Exchange Act of 1934, as amended, including without limitation,
Schedule 13D, Schedule 13G, Form 3, Form 4 and Form 5 (including any amendments
thereto). The Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Schedule 13D, Schedule 13G, Forms 3, 4
and 5 with regard to his or her ownership of or transactions in securities of
Amneal Pharmaceuticals, Inc., unless earlier revoked in writing. The undersigned
acknowledges that Denis Butkovic and Chris Daly are not assuming any of the
undersigned's responsibilities to comply with Section 13 or Section 16 of the
Securities Exchange Act of 1934, as amended.
By: /s/ Jason Daly
Name: Jason Daly
Date: February 22, 2023